Contact Us
Drug Search Results
More Filters [+]

Opaganib

Alternative Names: opaganib, abc294640, yeliva
Latest Update: 2024-12-02
Latest Update Note: News Article

Product Description

Opaganib, a first-in-class new chemical entity, is a sphingosine kinase-2 (SK2) selective inhibitor in oral pill form, with proposed dual anti-inflammatory and antiviral activity. Opaganib’s unique mechanism is host-targeted and therefore expected to be effective against emerging viral variants. (Sourced from: https://www.redhillbio.com/our-programs/pipeline/opaganib/covid-19/default.aspx)

Mechanisms of Action: SK2 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: Orphan Drug - Neuroblastoma *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: RedHill Biopharma
Company Location: TEL AVIV L3 64739
Company CEO:
Additonal Commercial Interests: Kukbo

Clinical Description

Map of Global Clinical Trials for Opaganib

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Cholangiocarcinoma|Klatskin Tumor

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
ABC-108

P2

Completed

Klatskin Tumor|Cholangiocarcinoma

2022-06-21

57%

Recent News Events

Date

Type

Title

12/10/2024

News Article

 Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development

12/02/2024

News Article

 RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court

10/28/2024

News Article

 RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND

10/22/2024

News Article

 RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury

05/05/2024

PubMed

 Opaganib Downregulates N-Myc Expression and Suppresses In Vitro and In Vivo Growth of Neuroblastoma Cells.

04/01/2024

PubMed

 Sphingosine-1-Phosphate Inhibition Increases Endoplasmic Reticulum Stress to Enhance Oxaliplatin Sensitivity in Pancreatic Cancer.

03/05/2024

PubMed

 Combined Antitumor Effect of the Serine Protease Urokinase Inhibitor Upamostat and the Sphingosine Kinase 2 Inhibitor Opaganib on Cholangiocarcinoma Patient-Derived Xenografts.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions